anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
NEW MATERIAL:A compound expressed by formula I (R1 is lower alkyl; R2 is H or halogen). EXAMPLE:R-(-)-N-[2-(3-aminosulfonyl-4-methoxyphenyl)-1-methyl ethyl]2-(5- fluoro-2-methoxyphenoxy)acetamide. USE:Useful as synthetic intermediate of phenoxyethylamine derivative useful as antihypertensive drug and remedy for dysuria. Furthermore, itself is very useful as an antihypertensive drug and remedy for dysuria. PREPARATION:Acetamide derivative expressed by formula II (R3 is Br or methyl sulfonyloxy) is reacted with phenol derivative expressed by formula III in a solvent such as N,N-dimethyiformamide at a temperature between room temperature and reflux temperature of the solvent using a base (e.g. potassium carbonate) as deoxidizer to afford the compound expressed by formula I.
Background: Getting ready for a colonoscopy is difficult and involves a lot of steps. The information given to patients is very important to adherence to treatment. The investigators have created a novel smart phone application (SPA) aimed to increased bowel preparation quality and patient satisfaction, using different educational tools.

Methods: The investigators have performed a prospective, endoscopist-blinded, randomized, controlled trial. The investigators have enrolled 260 outpatients owners of a smartphone. Patients were randomly allocated to two different protocols: instructions provided by SPA (SPA group; n=108) or written instructions with visual aids (control group; n=152). All procedures were performed in afternoon time and patients received the same purgative regimen (2-L PEG solution plus ascorbic acid), in a full-dose same-day regimen. The day before colonoscopy (Baseline), patients initiated low fiber diet. The study was designed to detect an improvement in quality of bowel preparation using the Harefield Cleansing Scale (HCS) scale. The effect of protocol on patient satisfaction was assessed with a specific questionnaire at time of the colonoscopy.
Experimental group: At the end of lung resection, lung sutures and 1.5 cm of lung parenchyma on each side will be covered by Hemopatch. No additional measures for preventing air leak will be indicated. In the case of massive air leak in spite of the use of Hemopatch, each surgeon will decide on the indication of additional sutures of tissue plasties. These cases will be accounted for failures on an intention to treat basis.
An electronic medical record data analysis system and an electronic medical record data analysis method are provided. The electronic medical record data analysis system includes a storage device and a processor. The storage device is used for storing an electronic medical record data analysis module and a post-processing module. The processor obtains an electronic medical record data. The processor executes the electronic medical record data analysis module to analyze the electronic medical record data and generate a plurality of disease diagnosis codes and a plurality of correlation degree scores corresponding to the electronic medical record data. The processor sorts the disease diagnosis codes according to the plurality of correlation degree scores to generate an initial list, and executes a post-processing module to post-process the initial list according to preset coding rules. The processor generates a recommendation list from the post-processed initial list.
1. Technical Result Increase in stability of crystalline form.         2. Essence A crystalline form diffraction pattern obtained on a diffractometer by means of K alpha radiation has diffraction peaks corresponding to 2theta angles: 5.735, 9.945, 11.500, 13.780, 14.930, 15.225, 17.980, 19.745, 21.575, 22.170, 24.505, and 27.020 degrees.  A crystalline form of compound of the formula (I)    is obtained by contacting the compound of formula (II), the structure of which is provided in the description with a phosphorylating agent with the subsequent reduce of the resultant compound with a reducing agent in a suitable solvent and adding to the resultant compound a source of calcium ions in the presence of a suitable solvent.          3. Field of Application Medicine.               Tables: 2
PURPOSE: To obtain a highly sensitive insoluble derivative having mechanical strength obtained by introducing optically dimerizable crosslinking groups into hyaluronic acid in a very low degree of the introduction while keeping characteristics essential to the acid and capable of being easily produced in a short time. CONSTITUTION: This optically cross-linkable hyaluronic acid derivative is a derivative into which 0.005-0.05 optically dimerizable cross-linking group per 2 sugar units of hyaluronic acid is introduced. The number average molecular weight of hyaluronic acid is 100,000-5,000,000. The cross-linking group is introduced by forming an amide bond between carboxylic group in hyaluronic acid. The cross-linking agent comprises a spacer and a cinnamoyl group having substituted groups or functional groups on a benzene ring. The spacer is an amino acid, a peptide, etc. The cross-linking group is expressed by formula I or II [R1 and R2 are each H, a lower alkyl; Ph is phenyl; (n) is 2-18; R3 is an alkyl; -Ph- is paraphenylene; (m) is 1-6 and (h) is 1-18]. A cross-linked cyclobutane group may be formed between the cross-linking groups themselves.  The method for producing the optically cross-linkable hyaluronic acid derivative is to prepare an aqueous solution of hyaluronic acid and introduce cross-linkable groups in the presence of a water soluble carbodiimide and a condensation assistant.
The invention belongs to the technical field of microorganisms, and particularly relates to an application of bacillus coagulans BC66 as an antioxidant. The strain has strong in-vitro free radical scavenging capacity after in-vitro antioxidant index screening and evaluation. The DPPH removing capacity is 66.79 percent. The bacillus coagulans BC66 has excellent high-temperature resistance, the survival rate of spores is 98% after the bacillus coagulans is treated at the high temperature of 120 ℃ for 10min, and the survival rate of the bacillus coagulans powder in the high-temperature feed pelleting process is up to more than 90%. The invention also provides application of the bacillus coagulans BC66 as an antioxidant feed additive. The bacillus coagulans BC66 can effectively improve the activities of SOD enzyme and catalase in the serum of yellow-feathered broilers, reduce the content of MDA in the serum, enhance the oxidation resistance of the yellow-feathered broilers, improve the immunity level of organisms and improve the production performance of animals.
Most first trimester aspiration abortions are performed in the outpatient setting with a paracervical block and nonsteroidal anti-inflammatory drugs (NSAIDs) as the only analgesics. Yet first trimester aspiration pain control is often inadequate with 26-32% of women reporting that they experienced severe pain. Moderate sedation and general anesthesia are not readily available, and investigations on opioids and anxiolytics have consistently found them ineffective for first trimester aspiration abortion pain. In 2018, The National Academies of Sciences, Engineering, and Medicine (NASEM) recommended research to improve pain relief. Limited data indicate that acupuncture is valuable in dysmenorrhea and for labor pain, conditions in which pain may be similar to that experienced during aspiration abortion.

This randomized trial will recruit women seeking first trimester aspiration abortion. This study will evaluate two types of auriculotherapy applied to selected acupoints on the external ear. The study treatments are acupressure using gold beads and acupuncture using Pyonex needles; both are applied to the ear using adhesive disks. A control group will receive the adhesive disks alone. All participants will receive usual care for their aspiration abortion procedure, including a paracervical block and ibuprofen for pain management. The investigators will query the participants regarding pain and anxiety immediately after their procedure, in person, on the day of their procedure.
OBJECTIVES: To compare and measure post-operative outcomes among various surgical techniques for reducing inferior turbinate hypertrophy (ITH), and to identify the factors associated with the clinical outcomes of turbinoplasty in patients with this condition.
METHODS: A cross-sectional study was carried out from January 2021 to December 2022 at the Otorhinolaryngology Department of King Abdulaziz Medical City in Riyadh, Saudi Arabia. A total of 301 adult patients with ITH were included and were divided into different groups. Postoperative follow-up assessments were completed after one week, one month, and 6 months to evaluate outcomes and complications associated with each surgical technique; descriptive analysis, cross-tabulation, and exact logistic regression were utilized as data analysis methods.
RESULTS: Most patients in both groups experienced partial or complete improvement after surgery, with 92% showing positive outcomes. Common clinical signs included deviated nasal septum deviation and external nasal deformity, while nasal obstruction was most frequently reported as the primary symptom. Post-surgery bleeding occurred in 3.7% of cases; no adhesions were noted. Microdebrider, medial flap, out-fracture, and submucosal diathermy techniques all demonstrated significantly higher improvement rates than others.
CONCLUSION: The identified techniques with higher improvement rates offer evidence-based guidance for selecting optimal surgical approaches, while the study's limitations warrant further prospective research to validate these findings. Ultimately, it contributes valuable knowledge to the field of otorhinolaryngology, aiming to enhance patient outcomes and improve the management of ITH worldwide.
<P>PROBLEM TO BE SOLVED: To carry out in-situ gel formation of a pectic substance.  <P>SOLUTION: A composition, a method for preparation and a method for use of a pectin in-situ gelling formulation for delivery and sustained release of a physiologically active agent to the body of an animal are provided. The pectin is isolated from Aloe vera. One object is to provide a composition for controlled or sustained release of the physiologically active agent in the body of the animal. Another object is to provide a transparent polymer solution wherein no dramatic increase in gel cloudiness is created beyond certain concentration ranges. Preferably, the composition can prepare an in-situ gel at low concentrations.  <P>COPYRIGHT: (C)2009,JPO&INPIT
The present invention relates to an AI care assistance and emergency evacuation assistance system, including a servo host, a sensing alarm device, a status and image tracking device, an environment and sound effect monitoring device, an environment and lighting monitoring device, and an environment and emergency evacuation monitoring device. The sensing alarm device is configured to detect a blood pressure, a heart rate, blood oxygen and a body temperature of each care recipient (resident). The status and image tracking device which has a general recording function and uses image recognition for environmental status and tracking is configured to monitor on-bed and out-of-bed status, confirm whether caregivers are attending work, and detect flames and smoke at the locations of all care recipients (residents) and public spaces. The environment and sound monitoring device is configured to detect sounds of the care recipients (residents) in various situations, and turn on and off the background music in each public space during the day and night. The environment and lighting monitoring device is configured to detect the brightness of a lighting device in each area of the care space for automatic adjustment and turn-on/turn-off, and at the same time detect the temperature and humidity data of each environment in the care space, so as to adjust a temperature of an air conditioning system and adjust the turn-on/turn-off of an indoor humidity device. The environment and emergency evacuation monitoring device is configured to detect flames and smoke, and can detect and provide the best escape route and the location of each care recipient (resident) or caregiver for emergency evacuation, so as to assist the caregivers and disaster relief personnel to know environmental conditions to shorten disaster relief time and reduce casualties.
All participants will come to the Stanford University campus for their baseline, week 6, and week 22 (end of study) tests. Prior to starting the assigned intervention, all participants will undergo a supervised (by study dietitian) week of weight maintenance, followed by baseline tests including insulin resistance test (SSPG), Standardized Meal Tolerance Test (for hormone and metabolite profiles), oral glucose tolerance test (OGTT), DXA and MRI scans (to quantify total, regional, and intrahepatic fat), and a subcutaneous periumbilical adipose tissue needle biopsy. Following baseline testing, participants begin tirzepatide vs diet. weight loss will be aggressive for the first six weeks with diet to match the tirzepatide weight loss that is expected. After week 6 weight loss will occur naturally on both without matching. Patients will see the dietitian and coordinator every two weeks to review diet and physical activity, and evaluate tolerability/side effects, and obtain morning weight at Stanford. The metabolic tests, regional fat scans, and biopsy will be repeated at week 6 and week 22.
The mechanism of action of tacrolimus in atopic dermatitis is not known. While the following have been observed, the clinical significance of these observations in atopic dermatitis is not known. It has been demonstrated that tacrolimus inhibits T-lymphocyte activation by first binding to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin, and calcineurin is then formed and the phosphatase activity of calcineurin is inhibited. This effect has been shown to prevent the dephosphorylation and translocation of nuclear factor of activated T-cells (NF-AT), a nuclear component thought to initiate gene transcription for the formation of lymphokines (such as interleukin-2, gamma interferon). Tacrolimus also inhibits the transcription for genes which encode IL-3, IL-4, IL-5, GM-CSF, and TNF-α, all of which are involved in the early stages of T-cell activation. Additionally, tacrolimus has been shown to inhibit the release of pre-formed mediators from skin mast cells and basophils, and to down regulate the expression of FcεRI on Langerhans cells.
Introduction and Aim: With the increase in life expectancy in cancer, it gains importance in the care process and the problems experienced by caregivers. However, the problems experienced by individuals caring for cancer patients are often ignored. The most common problems faced by cancer caregivers are sadness, anxiety, sleep disorders, and fatigue. Although reflexology has positive effects on sleep and anxiety in different patient groups, there is no study on its effectiveness in cancer caregivers. The aim of this study was to evaluate the effectiveness of reflexology on sleep and anxiety of caregivers.

Materials and Methods: The study was conducted as a double-blind placebo-controlled design. After the groups were determined with block randomization, the reflexology investigation was applied to the experimental group for three consecutive days, while for the placebo group, the hands were moved around the foot for the same periods but no deep stimulation was applied. On the fourth day, a sociodemographic diagnostic form, state anxiety scale, and Richard-Campbell Sleep Scale were administered to the participants by a blinded researcher. Data were analyzed with SPSS 25.0 package program. Written permission was obtained from the relevant ethics committee, hospital and participants to conduct the study.
Fluticasone Propionate Cream, 0.05% may be used in adult and pediatric patients 3 months of age or older. Safety and efficacy of Fluticasone Propionate Cream, 0.05% in pediatric patients for more than 4 weeks of use have not been established (see PRECAUTIONS: Pediatric Use). The safety and efficacy of Fluticasone Propionate Cream, 0.05% in pediatric patients below 3 months of age have not been established. 

Atopic Dermatitis: Apply a thin film of Fluticasone Propionate Cream, 0.05% to the affected skin areas once or twice daily. Rub in gently. 

Other Corticosteroid-Responsive Dermatoses: Apply a thin film of Fluticasone Propionate Cream, 0.05% to the affected skin areas twice daily. Rub in gently. 

    As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary.

Fluticasone Propionate Cream, 0.05% should not be used with occlusive dressings. Fluticasone Propionate Cream, 0.05% should not be applied in the diaper area, as diapers or plastic pants may constitute occlusive dressings. 

Geriatric Use: In studies where geriatric patients (65 years of age or older, see PRECAUTIONS) have been treated with fluticasone propionate cream, 0.05% safety did not differ from that in younger patients; therefore, no dosage adjustment is recommended.
The present invention relates to a skin barrier improving and whitening cosmetic composition containing a birch sap and an herbal medicinal extract, and a cosmetic material including the same. The skin barrier improving and whitening cosmetic composition according to the present invention includes a birch sap and an herbal medicinal extract. The herbal medicinal extract includes a birch extract, a sea buckthorn extract, an orange extract, and a white willow extract. According to the present invention, the cosmetic composition including a birch sap and an herbal medicinal extract is produced to have effects in whitening skin, removing free radicals, and moisturizing skin, to prevent aging, to improve health of skin, to alleviate dry skin, and to improve skin barrier states. Also, bodily waste in makeup and corneum and pores of skin is cleanly removed, and skin troubles and skin irritation are minimized. Moreover, dry skin can be moistly and smoothly beautified.
The participant receives the control condition for 6 months following baseline measurements. After 6 months, the baseline measurements are repeated and then the participant receives the intervention.
PURPOSE: An extraction and purification method of active substance from Gentianae Macrophyllae radix using alcohol aqueous solution and non-polar solvent, and the crudedrug composition containing the extract are provided. CONSTITUTION: An extraction method of Gentianae Macrophyllae radix comprises the following steps: a) Gentianae Macrophyllae radix is extracted with water and filtered; b) filtered solution is separated using 0.7-1.2 pts.wt. of low alcohol of vesicant based on 1 pts.wt of filtered solution; c) 3-5 pts.wt. of ethyl alcohol is added in remaining aqueous solution from separation based on 1pts.wt. of the remaining aqueous solution then concentrated under reduced pressure at 60-70°C; d) the extract from concentration is freeze dried to produce powder extract. The powder extract of Gentianae Macrophyllae radix can be used as an active substance of antiinflammatory analgesics, and tablet and syringe of the Gentianae Macrophyllae radix extract are developed for convenient medication.
Although survival from breast cancer has dramatically increased, many will develop recurrent, metastatic disease. Unfortunately, survival for this stage of disease remains very low. Activating the immune system has incredible promise since it has the potential to be curative. However, immune checkpoint blockade (ICB) which works through T cells has been largely disappointing for metastatic breast cancer. One reason for this is a suppressive myeloid immune compartment that is unaffected by ICB. Cholesterol metabolism and proteins involved in cholesterol homeostasis play important regulatory roles in myeloid cells. Here, we demonstrate that NR0B2, a nuclear receptor involved in negative feedback of cholesterol metabolism, works in several myeloid cell types to impair subsequent expansion of regulatory T cells (Tregs); Tregs being a subset known to be highly immune suppressive and associated with poor therapeutic response. Within myeloid cells, NR0B2 serves to decrease many aspects of the inflammasome, ultimately resulting in decreased IL1β; IL1β driving Treg expansion. Importantly, mice lacking NR0B2 exhibit accelerated tumor growth. Thus, NR0B2 represents an important node in myeloid cells dictating ensuing Treg expansion and tumor growth, thereby representing a novel therapeutic target to re-educate these cells, having impact across different solid tumor types. Indeed, a paper co-published in this issue demonstrates the therapeutic utility of targeting NR0B2.
BACKGROUND: CeRNA axis is an important way to regulate the occurrence and development of Nasopharyngeal carcinoma (NPC). Although the research on inducing cuproptosis of tumor cells is in the early stage of clinical practice, its mechanism of action is still of great significance for tumor treatment, including NPC. However, the regulation mechanism of cuproptosis in NPC by ceRNA network remains unclear.
METHODS: The ceRNA network related to the survival of nasopharyngeal carcinoma related genes was constructed by bioinformatics. Dual-luciferase reporter assay and other experiments were used to prove the conclusion.
RESULTS: Our findings indicate that the AC008083.2/miR-142-3p axis drives STRN3 to promote the malignant progression of NPC. By performing enrichment analysis and phenotypic assays, we demonstrated that the changes in the expressions of AC008083.2/miR-142-3p/NPC can affect the proliferation of NPC. Mechanistically, luciferase reporter gene assays suggested that AC008083.2 acts as a ceRNA of miR-142-3p to regulate the content of STRN3. Furthermore, the regulations of STRN3 and the malignant progression of NPC by AC008083.2 depends on miR-142-3p to some extent.
CONCLUSIONS: Our study reveals an innovative ceRNA regulatory network in NPC, which can be considered a new potential target for diagnosing and treating NPC.
BACKGROUND: Mastectomies are commonly performed and strongly associated with chronic postsurgical pain (CPSP), more specifically termed postmastectomy pain syndrome (PMPS), with 25-60% of patients reporting pain 3 months after surgery. PMPS interferes with function, recovery, and compliance with adjuvant therapy. Importantly, it is associated with chronic opioid use, as a recent study showed that 1 in 10 patients continue to use opioids at least 3 months after curative surgery. The majority of PMPS patients are women, and, over the past 10 years, women have outpaced men in the rate of growth in opioid dependence. Standard perioperative multimodal analgesia is only modestly effective in prevention of CPSP. Thus, interventions to reduce CPSP and PMPS are urgently needed. Ketamine is well known to improve pain and reduce opioid use in the acute postoperative period. Additionally, ketamine has been shown to control mood in studies of anxiety and depression. By targeting acute pain and improving mood in the perioperative period, ketamine may be able to prevent the development of CPSP.
METHODS: Ketamine analgesia for long-lasting pain relief after surgery (KALPAS) is a phase 3, multicenter, randomized, placebo-controlled, double-blind trial to study the effectiveness of ketamine in reducing PMPS. The study compares continuous perioperative ketamine infusion vs single-dose ketamine in the postanesthesia care unit vs placebo for reducing PMPS. Participants are followed for 1 year after surgery. The primary outcome is pain at the surgical site at 3 months after the index surgery as assessed with the Brief Pain Inventory-short form pain severity subscale.
DISCUSSION: This project is part of the NIH Helping to End Addiction Long-term (HEAL) Initiative, a nationwide effort to address the opioid public health crisis. This study can substantially impact perioperative pain management and can contribute significantly to combatting the opioid epidemic.
TRIAL REGISTRATION: ClinicalTrials.gov NCT05037123. Registered on September 8, 2021.